What's in Sun Pharma Advanced Research Company Limited's pipeline?

Sun Pharma Advanced Research Company Limited has 38 drugs in our index: 0 marketed, 0 filed, 8 in Phase 3, 9 in Phase 2, 21 in Phase 1.

Which companies overlap with Sun Pharma Advanced Research Company Limited's portfolio?

Top competitors by shared drug class: HK inno.N Corporation, Hoffmann-La Roche, BeBetter Med Inc, EMS, Hanlim Pharm. Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sun-pharma-advanced-research-company-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sun Pharma Advanced Research Company Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sun Pharma Advanced Research Company Limited pipeline: 0 marketed, 0 filed, 8 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 8 Phase 3 9 Phase 2 21 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
SPARC0921	SPARC0921	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
SPARC1104 modified dose regimen I	SPARC1104 modified dose regimen I	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1	Oncology
SPARC1104 modified dose regimen II	SPARC1104 modified dose regimen II	phase 3
Reference0912	Reference0912	phase 3	Immune checkpoint inhibitor	PD-1	Oncology
SPARC1104 modified dose regimen III	SPARC1104 modified dose regimen III	phase 3
SDN-037	SDN-037	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
SPARC0912	SPARC0912	phase 3	Histone deacetylase (HDAC) inhibitor	Histone deacetylase (HDAC)	Oncology
SPARC0913	SPARC0913	phase 3

Therapeutic area mix

Oncology · 3
Diabetes · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

HK inno.N Corporation · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
BeBetter Med Inc · 2 shared drug classes
EMS · 2 shared drug classes
Hanlim Pharm. Co., Ltd. · 2 shared drug classes
Hanmi Pharmaceutical Company Limited · 2 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sun Pharma Advanced Research Company Limited:

Cite this brief

Drug Landscape (2026). Sun Pharma Advanced Research Company Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sun-pharma-advanced-research-company-limited. Accessed 2026-05-16.